Insulin Human [rDNA origin] Articles
Pfizer makes another move into generics in deal with Strides Arcolab; enters into discovery accord with Ensemble
7 January 2010
Pfizer takes full rights to Exubera for $1.3B
22 December 2008
Pfizer's 3rd-qtr 2008 profit triples due to Exubera write-off; revenues flat at $12B
27 October 2008
EMEA orders lung cancer warning for Pfizer's Exubera
23 June 2008
MannKind suspends insulin partnership talks
21 April 2008
Pfizer
14 April 2008
Lilly pulls out of inhaled insulin development
17 March 2008
Pfizer announces Exubera job cuts; Wyeth may cut workforce 10%
4 February 2008
Novo Nordisk settles law suit with Pfizer over Exubera
17 December 2007
Raft of pending patent expiries threaten cardiovascular blockbusters
10 December 2007
Pfizer looks to increase outsourcing to 30%
10 December 2007
Stock Commentary - New York week to Nov 19
26 November 2007
Pfizer and Nektar resolve Exubera issues
19 November 2007
Stock Commentary - New York week to October 22, 2007
29 October 2007
Pfizer's 1st-qtr profits tumble 17.5%
30 April 2007
Pulmonary drug-delivery market to reach $34.5B by 2010
16 April 2007
Exubera shows safety and efficacy
7 February 2007
Novo's motion to block US Exubera denied
22 December 2006
EASD panels recommend insulin acceptance, and highlight shortfalls in DPNP therapy
25 September 2006
Exubera use not complicated by respiratory infections
25 September 2006
Emerging diabetes management solutions boost European market
14 August 2006
Pfizer sued by Novo for patent infringement
7 August 2006
Pfizer rejects UK site, cites bureaucracy
3 July 2006
Global diabetes drug market worth $15B in 2005
22 May 2006
NICE says inhaled insulin "too expensive" for UK, Pfizer appeals to health professionals
24 April 2006
EC OKs Pfizer's Exubera for diabetes
6 February 2006
FDA approves Pfizer's Exubera inhaled insulin
6 February 2006
Sanofi-Aventis/Pfizer's Exubera sees good efficacy
19 September 2005
Pfizer Germany sees 2006 recovery
12 September 2005
Sanofi ups guidance as 2nd-qtr EPS rises 24.7%
5 September 2005
Pfizer/S-A's Exubera shows good results
27 June 2005
UPDATE: Pfizer's $4B cost-saving plan pleases investors, despite lower 2005 EPS forecast
11 April 2005
Pfizer and Sanofi-Aventis file Exubera
14 March 2005
Long-term benefits with use of Exubera
20 September 2004
Positive Aventis' Exubera data at ADA
14 June 2004
Aventis/Pfizer's Exubera filing accepted by EMEA
15 March 2004
Detailing rejection of Sanofi bid, Aventis says it is opportunistic, under-values firm
15 March 2004
Aventis still argues against Sanofi bid
16 February 2004
Stock Commentary - Europe
30 June 2003
Exubera superior to oral drugs in diabetes
24 June 2002
Exubera effective, but lung function declines
13 May 2002
Aventis' Exubera to be filed by year-end?
18 February 2002
ViroPharma's NDA for Picovir accepted
1 October 2001
Global pulmonary drug delivery market forecasts
24 September 2001
Aradigm's AERx iDMS shown not to induce asthma
11 September 2001
Emisphere gets no lift from oral insulin data
10 September 2001
Stock Commentary - Europe
26 July 2001
Update - Pfizer second-quarter net income leaps 31%
18 July 2001
Exubera outperforms injectable insulin
26 June 2001
Inhaled insulin found safe after two years
24 May 2001
Showing 1-65 of 65 articles
- 1
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
